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Introduction
Twin–twin transfusion syndrome (TTTS) complicates
approximately 1 in 5 of all monochorionic, diamniotic
twin pregnancies [1]. TTTS could also affect triplet or
higher order multiple gestations, in which at least two
fetuses are monochorionic [2,3]. In monoamniotic
twins, the lack of a dividing membrane precludes the
combined presence of polyhydramnios and oligohy-
dramnios. In these patients, the syndrome can be 
suspected by the presence of polyhydramnios and dif-
ferences in bladder filling of the two fetuses [4].
The etiology of TTTS appears to result from a net
unbalanced flow of blood between two monochorionic
fetuses through placental vascular communications,
which results in a donor twin and a recipient twin.
Although actual documentation of the unbalanced
blood flow remains elusive [5], vascular anastomoses
might be responsible for the development of TTTS if the
vascular design is such that it forces a net flow from
donor to recipient [5]. Alternatively, vascular anasto-
moses might play a passive role in the development of
the syndrome, but nonetheless allows its development.
This is the case with monochorionic twins who are dis-
cordant for congenital heart disease, cardiomyopathies,
cord anomalies, or other conditions associated with
uneven hemodynamic competence [4].
When the onset of this condition occurs before 
26 weeks of gestation, there is a significant associated
risk of fetal loss, perinatal death, and subsequent hand-
icap in survivors [6]. If untreated at its early onset, severe
TTTS has a dismal prognosis, with perinatal mortality
rates > 90% [7], and > 30% of survivors suffering from
associated neurodevelopmental anomalies [8].
The poor outcome of untreated TTTS has led to the
introduction of a number of treatments. Most of them,
however, are subject to controversy. Amnioreduction
and endoscopic laser ablation of vascular anastomoses
have both been shown to reduce perinatal mortality in
an uncontrolled series [9]. Nevertheless, which is the
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optimal treatment for TTTS, serial amniocentesis or
laser, has long been an issue of debate [4].
Amnioreduction is a relatively simple and widely
available treatment that involves repetitive percuta-
neous removal of large volumes of amniotic fluid (usu-
ally in excess of 1–2 L on each occasion). The rationale
for this technique is to prevent preterm labor related
to hydramnios. The rationale for endoscopic laser
coagulation is to interrupt the placental vascular com-
munications between the twins on the chorionic plate,
a technique advocated in a few specialist centers [6].
The argument over which treatment is superior lasted
for years until the first and only randomized trial on
interventions for TTTS was published, comparing laser
to amnioreduction [10]. It was proven that the laser
group had a higher likelihood of the survival of at least
one twin to 28 days of age (76% vs. 56%; relative risk of
the death of both fetuses, 0.63; 95% confidence inter-
val, 0.25–0.93; p = 0.009) and to 6 months of age
(p = 0.002). Infants in the laser group also had a lower
incidence of cystic periventricular leukomalacia (6% vs.
14%; p = 0.02) and were more likely to be free of neuro-
logic complications at 6 months of age (52% vs. 31%;
p = 0.003). This study demonstrated that fetoscopic-
guided laser ablation of chorionic plate vascular anas-
tomoses was a more favorable choice as a first-line
treatment for severe TTTS diagnosed before 26 weeks.
It has been recognized that laser surgery for TTTS
should be available in fetal medicine units that are man-
aging at least 20 cases per year [9]. The incidence of
monozygotic twins is constant at 4 per 1,000 births [11].
Currently in Taiwan, with an estimated 200,000 births
per year, 800 sets of monozygotic twins are expected to
be delivered, with 80 cases of TTTS predicted to occur
each year. It is, therefore, recommended that obstetri-
cians be familiar with the diagnosis of TTTS as well as
the indications, procedures and the complications of
laser treatment for this disorder.
History of Fetoscopic Laser 
Therapy for TTTS
The basic technique was pioneered by De Lia in the
1980s. In 1983, De Lia saw a case of TTTS at 23
weeks’ gestation and treated the mother with digoxin
[12]. Both fetuses eventually survived, but the hydropic
recipient twin was later found to be affected with cere-
bral palsy. After examining the placenta, De Lia found
that only a single arteriovenous anastomosis existed
between the two involved fetuses on the placenta. At
that time, he came up with the idea that if he could
block the single arteriovenous anastomosis, he might
be able to treat the disease. He then began a series of
experiments with a sheep model using a YAG laser
[13]. Eventually, his group performed the first laser treat-
ment in 1988 [14], a procedure known as fetoscopic
laser occlusion of chorioangiopagus vessels (FLOC).
The second person who contributed to the develop-
ment of this technique is Ville. In the original description
of FLOC by De Lia et al [14], laparotomy was performed
under general or regional anesthesia to explore the
uterus, followed by insertion of an endoscope into the
amniotic cavity. Ville, on the other hand, performed
laser therapy for TTTS via a percutaneous approach
using a 2.0-mm fiber-optic endoscope without resorting
to laparotomy, thereby making the technique less inva-
sive [15]. According to De Lia et al, the identification
of the target vessels for coagulation was based on their
endoscopic appearance [14]. The described technique
was perceived by other investigators to be difficult, per-
haps due to the lack of distinct anatomical landmarks or
accurate knowledge of placental anatomy [4]. Ville et al
suggested using the dividing membrane as the landmark
to identify the communicating vessels [15], and that all
vessels of the donor twin crossing the dividing membrane
into the sac of the recipient twin should be photocoag-
ulated. This approach was easier to understand since the
membrane that separated the fetuses would also serve
as a landmark that divided the placenta.
Finally, we should mention Quintero who proposed
the staging classification of TTTS that is now used
worldwide [16]. In addition, Quintero devised a tech-
nique called selective laser photocoagulation of com-
municating vessels (SLPCV) [17]. SLPCV selectively
coagulates communicating vessels and preserves the
non-communicating vessels even if they cross the
dividing membrane. In Ville et al’s description [15],
the advantage of coagulating all of the donor vessels
crossing the dividing membrane was to set up a stan-
dard using the dividing membrane as an anatomical
landmark reference, thus improving its reproducibility.
However, this nonselective ablation of all the crossing
vessels has been shown to increase the likelihood of
dual intrauterine fetal death in comparison to SLPCV
[18]. In Quintero et al’s description of SLPCV [17],
each placental artery is followed to its terminal end in
the placenta (arteries cross over veins), and a returning
vein from that cotyledon should be traced draining
back to the same twin. If blood is drained to the other
twin, then a deep arteriovenous anastomosis is pres-
ent. Arterioarterial or venovenous anastomoses are iden-
tified easily by noting lack of a terminal end for an artery
or a vein, respectively. SLPCV is associated with an 85%
success rate (likelihood that at least one fetus survives)
and a 3–5% risk of cerebral palsy. SLPCV compares
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favorably with the previous nonselective technique,
resulting in a lower rate of dual fetal demise (5.6% vs.
22%) [18]. Reliable techniques to treat patients with
anterior placentas have also been developed by Quintero
et al [19].
In the following sections, this article will focus pri-
marily on introducing the technique as developed by
Quintero et al, who have performed over 500 cases at
the Florida Institute for Fetal Diagnosis and Therapy at
St Joseph’s Women’s Hospital from 1996 to 2005.
Recently, in November 2005, Dr Quintero joined the
University of South Florida as professor and director of
the division of maternal–fetal medicine in the depart-
ment of obstetrics and gynecology there.
Diagnosis of TTTS
About 25% of cases transferred to the Florida Institute
for Fetal Diagnosis and Therapy with the suspected
diagnosis of TTTS later turned out not to fulfill the
TTTS criteria. Those cases varied from simple amniotic
fluid volume discordance to isolated polyhydramnios
and isolated oligohydramnios [4].
The diagnosis of TTTS is based on the following
sonographic findings: (1) polyhydramnios, ≥ 8 cm of
maximum vertical pocket (MVP) in the recipient twin;
(2) oligohydramnios, MVP ≤ 2 cm in the donor twin;
(3) single placenta, thin dividing membrane, and simi-
lar external genitalia.
In a study by Danskin and Neilson of 178 twin
pairs [20], only four pairs had a hemoglobin difference
> 5 g/dL and a weight difference > 20%, and none of
those pregnancies showed evidence of polyhydramnios
or oligohydramnios. Similarly, percutaneous umbilical
blood sampling in six TTTS patients failed to show
hemoglobin differences > 5 g/dL, except in one preg-
nancy [21]. Consequently, the previous pediatric crite-
ria of a hemoglobin difference > 5 g/dL and a weight
difference > 20% are no longer applicable [4].
The most widely used criteria for TTTS staging is
that of Quintero et al [16], and is as follows:
● Stage I—the bladder of the donor twin is still visi-
ble, and Doppler studies are still normal;
● Stage II—the bladder of the donor twin is not 
visible (during the length of the examination, usually
1 hour), but Doppler studies are not critically
abnormal;
● Stage III—Doppler studies are critically abnormal in
either twin and are characterized as absent or reverse
end-diastolic velocity in the umbilical artery, reverse
flow in the ductus venosus, or pulsatile umbilical
venous flow;
● Stage IV—presence of ascites, pericardial or pleural
effusion, scalp edema, or overt hydrops;
● Stage V—demise of one or both fetuses.
During expectant management of patients with
TTTS, one may see no progression from one stage to the
next, sequential change, or non-sequential progression
of disease. Regardless of whether or not the disease
follows an orderly pattern, the proposed staging system
has prognostic value [4].
Fetoscopic Laser Therapy
Inclusion criteria
Since the first randomized trial on interventions for
TTTS, comparing laser to amnioreduction, was pub-
lished [10], it has been recognized that first-line treat-
ment for all stages of TTTS diagnosed before 26 weeks
is laser treatment. However, since laser treatment has
only been advocated in a few specialist centers [6],
and < 10% of pregnancies in the aforementioned study
were in Quintero stage I or IV [10], it is premature to
conclude that laser coagulation should be the first-line
treatment in all cases [22]. For stage I cases in particu-
lar, Quintero et al found that the prognosis was not
significantly different between stage I TTTS treated by
amnioreduction and that treated by laser therapy
[23]. It is possible to follow stage I TTTS patients
expectantly as long as the degree of polyhydramnios 
is not severe (MVP, 8–9 cm) and the cervical length is
adequate (> 2.5 cm), especially when the disease is
diagnosed after 22–24 weeks of gestation. Such preg-
nancies have a great chance of remaining stable and
not requiring invasive therapy [4].
The advantage of laser treatment for stage I TTTS is
that 95% of cases need only one procedure, as opposed
to cases treated by serial amnioreduction that usually
require multiple tappings. Therefore, laser treatment
may be a good alternative choice for early-onset stage I
TTTS if patients do not wish to receive multiple inva-
sive procedures as their pregnancy progresses.
In Chang Gung Memorial Hospital, we currently
recruit TTTS patients for laser operation using the fol-
lowing inclusion criteria: (1) Stage II, III and IV TTTS
with gestational age < 26 weeks; (2) Stage I TTTS with
gestational age < 22 weeks.
Contraindications
Not all TTTS cases are suitable candidates for laser
therapy. Cases with gestational age > 26 weeks when
fetuses are viable are not offered the fetoscopic sur-
gery option due to the invasiveness of the procedure
itself. Other contraindications for laser surgery include
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abnormal genetic studies, ruptured or detached mem-
branes, prior septostomy (a hole in the dividing mem-
brane; Figure 1), short (defined as < 2.5 cm) or dilated
cervix, preterm labor and placenta previa. Short cervix
and placenta previa are recognized as relative contraindi-
cations to laser surgery. In cases with severe TTTS but
with short cervix, postoperative cerclage of the cervix is
important.
If the distance of umbilical cord insertion of the two
involved fetuses is short, the communicating vessels
would be too large for photocoagulation. For fetal sur-
geons fresh in this field, such cases may be difficult for
them to handle. Quintero and his group have dealt with
cases of total anterior placenta and short distance
between the two cords in the two involved fetuses using
laser operation with great skill; even in cases with
detached membranes, they could perform laser therapy
with or without the help of amniopatch [24]. For an old
hand with great familiarity and maturity of skill, more
difficult cases can be managed. New fetal surgeons,
however, should take great care in selecting TTTS cases
for fetoscopic laser therapy so that they do not end up
with cases that are beyond their capacity or experience.
Fetoscope
Several manufacturers have developed equipment that
is specifically designed for fetal surgery. Currently, the
experience gathered with any type of fetoscope is limited
and there is no evidence that any one particular brand
of endoscope performs better than another [25]. The
main difference of design may lie in the way the work-
ing channel fits in. In some brands of fetoscope, the
working channel is built within the scope itself (such as
that from Richard Wolf GmbH, Knittlingen, Germany),
whereas in others, the working channel is attached to
the sheath (such as that from Karl Storz GmbH & Co.
KG, Tuttlingen, Germany; Figure 2). The advantage of
placing the working channel within the scope is that
there is no need to move the sheath during operation,
thus reducing the risk of tearing the membrane, while the
disadvantage is that the space within the scope is limited
due to sharing with the working channel, thereby
decreasing the scope’s field of vision. There are different
strategies for approaching the anterior placenta. Some
use curved or angled scopes [19]. In Storz’s designation,
the laser fiber can, through a special design, be curved,
but at the cost of fitting in a larger sheath (3.7 mm) as
compared with a smaller one (2.2 mm) for the posterior
placenta. The Wolf design offers a 70° scope to view the
placental vessels at a difficult angle but just for diagno-
sis not for operation.
Laser
We currently use Nd:Yag laser as the energy source to
photocoagulate TTTS placental communicating vessels.
Nd:Yag laser selectively heats up hemoglobin, so it can,
therefore, coagulate the placental vessels well. Because
of problems with its stability, however, the high power
output Nd:Yag laser machine, usually required to gener-
ate output as high as 50 watts, has become less avail-
able in recent years. In many other centers, the diode
laser is chosen as an alternate energy source for laser
treatment [26]. Usually, the diameter of the laser fiber
is < 600 μ (0.6 cm), so that it can pass through the
fetoscopic working channel. From our experience, a
400 μ fiber can pass through the working channel more
freely than a 600 μ fiber, but some brands of laser
machine cannot deliver high power output through a
400 μ fiber, with some delivering up to 20 watts of
energy only.
Ultrasound
During fetoscopic operation, a sonographer or sono-
graphist with a sonography machine should be present
in the operating room to assist with the surgery. Sono-
graphy not only serves to guide as the fetoscope enters
the uterus, but also monitors the status of the fetuses
during operation and the amount of amniotic fluid
before and after the operation. Smooth cooperation
between the sonographist and fetal surgeon is very
important for conducting successful fetal surgery.
Figure 1. Septostomy after amniocentesis.
Figure 2. A 0’ fetoscope with working sheath.
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Preoperative management
Usually, the patient is admitted on the same day as or
on the day before the operation. Prophylactic antibiotic
is administered routinely in the operating room before
laser surgery. Indomethacin suppository 100 mg is given
1 hour before surgery as prophylactic tocolysis. History
taking and physical examination to pick up factors that
can influence the operation, such as hyperthyroidism
and heart murmur, are very important.
Anesthesia
At Chang Gung, we used epidural anesthesia in our first
four cases, but one also received spinal anesthesia due to
epidural failure. Quintero, however, routinely applied
local anesthesia as he performed fetal surgery, while
the anesthetic doctor stood by.
Patient position
The position of the patient depends on the placenta
site. Supine position is usually sufficient for cases with
posterior placenta. In cases with fundal area placenta,
placing the patient in a lithotomy position may help to
effect a better approach to the communicating vessels.
Procedure
First, identify the possible vessels on the uterine wall,
choose a placenta free area, and then apply Doppler
mode to detect any vessels on the uterine wall that
could hamper the entry of the sheath. Because of poly-
hydramnios, we usually have no trouble finding a free
space to insert the scope. Quintero rarely needed to
insert the sheath transplacentally, but nevertheless,
according to Yamamoto et al, whether or not the feto-
scope is inserted transplacentally has no significant
effect on clinical outcome, despite the fact that inser-
tion through the placenta may carry a higher risk of
intra-amniotic bleeding [26].
Second, put the sheath and trocar into the uterus in
order to enter the recipient sac. If it is mainly posterior
wall placenta, then it is usually easy to enter the recipient
sac without septostomy, and there is usually no need to
put in a special instrument like an angled scope to shoot
the communicating vessels. If it is mainly anterior wall
placenta, then it is usually more difficult to enter the
recipient sac than if the placenta is posterior. In special
conditions such as if the free space is at the donor side
on entry into the uterus, septostomy may be unavoid-
able and specially designed instruments are needed to
shoot the communicating vessels.
Third, identify the communicating vessels. The ration-
ale for detecting the communicating vessels between
the two involved fetuses has been described by Quintero
et al [17]. A deep arteriovenous communication from
donor to recipient is identified if the artery originates
from the donor cord and ends in a cotyledon from
which the emerging vein runs towards the cord of the
recipient twin. Arteries appear darker in color and can
be seen to cross over veins. Superficial artery-to-artery
or vein-to-vein anastomoses are also coagulated and
are identified as vessels that do not have a terminal
end in the placenta, but rather continue their course
from one umbilical cord to the other. All vessels are
followed systematically from the point they cross the
intertwining membrane. This technique allows sparing
of vessels that are critical to the donor or the recipient
[18]. Under the fetoscope, those vessels that cross over
the dividing membrane but, through tracing their
course, appear as normal vessels, should be preserved
(Figure 3). The communicating vessels are categorized
as deep or superficial anastomosis. Deep anastomosis
is a placental artery in one fetus connected to a placen-
tal vein in another fetus (Figure 4). Superficial anasto-
mosis could be artery to artery (Figure 5) or vein to
vein (Figure 6). In Chang et al’s series [27], there were
about 4.2% of anastomoses that could not be totally
coagulated during fetoscopic operation by examining
placentae sent back for analysis after delivery. Incom-
plete coagulation of anastomoses can lead to persist-
ent TTTS, reverse TTTS, dual intrauterine fetal demise
or marked isolated discordant hemoglobin levels [28].
In that case, when there is doubt as to whether a vessel
is connecting or draining the placenta of only one
twin, it is better to coagulate it to minimize the risk of
leaving an anastomosis behind.
Fourth, laser photocoagulation is usually started
with 15–20 watts. If the gestational age is advanced or
the communicating vessels are large, it may be necessary
Figure 3. Normal perfused vessels with paired artery and vein.
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to increase the power of the laser to 25–30 watts. We
seldom use laser power > 35 watts.
Fifth, amnioreduction is performed by draining the
amniotic fluid to leave the MVP < 8 cm.
Sixth, the sheath is pulled out. After the fetoscope
and sheath are pulled out of the uterus, the insertion site
is checked by sonography for signs of bleeding. If there is
bleeding in the uterine wall, compression of the wound
from the abdominal wall will usually stop the bleeding.
Seventh, the surgeon then decides whether or not
to suture the abdominal wound. Usually, the wound is
left without suture.
Prognosis
Survival of at least one fetus has increased from 61%
to 83% with a selective technique, and dual fetal losses
have decreased from 22% to 5%, with a 4.2% neuro-
logic handicap rate [23].
Postoperative care
Patients remain in the hospital for 12–48 hours, and
complications such as maternal discomfort, vaginal
bleeding, premature rupture of membranes (PROM),
high temperature, and need for postoperative analgesia
have been reported. Cervical length before and after
operation are checked; if cervical length < 25 mm, then
a cerclage suture is put in. After laser therapy, ultrasound
examination should be performed daily during hospital-
ization. If there are no signs of PROM or infection, and
the donor bladder can be visualized, then the patient may
be discharged home and receive weekly clinic follow-up.
Complications
All published reports agree that this procedure carries
a minimal risk to the mother and that significant
maternal surgical complications are rare [9]. No
maternal death has been found to be a direct con-
sequence of the procedure. Yamamoto et al reported
amniotic fluid leakage into the maternal peritoneal
cavity in 13/175 (7.4%) cases and vaginal bleeding in
7/175 (4%) cases after surgery [26]. PROM has been
recognized as the most frequent complication of laser
therapy. In the Yamamoto et al series, PROM occurred
in 49 (28%) patients, at within 1 week of laser therapy,
between 8 and 21 days, and after 3 weeks in 7%, 5%,
and 17% of the cases, respectively [26].
Follow-up
Patients should be followed-up weekly, whether at 
the hospital where the surgery was performed or at 
the primary care hospital. Doppler studies of the 
middle cerebral artery, umbilical artery, umbilical vein
Figure 5. Communicating vessel from donor artery to recipi-
ent artery.
Figure 4. Communicating vessel from donor artery to recipi-
ent vein.
Figure 6. Communicating vessel from donor vein to recipient
vein.
and ductus venosus should be performed at weekly
intervals.
Delivery
In TTTS cases that do not receive laser therapy, mono-
chorionic twins are considered to be at high risk for
sudden transfusion throughout labor and delivery;
therefore, they are generally delivered by cesarean sec-
tion. In cases of TTTS treated by SLPCV, monochori-
onic twins are rendered functionally dichorionic, and
thus pose no danger for vaginal delivery if no other
obstetric contraindications exist.
Placentae should be examined for the site of laser
photocoagulation and any remaining residual com-
municating vessels, if any, that may have escaped
detection during operation (Figure 7).
Long-term Neurologic Outcomes of
Fetuses Post Laser Treatment
There are reports stating that severe cerebral lesions in
TTTS treated with fetoscopic laser surgery are frequent
and result mainly from antenatal injury [29]. A 14%
incidence of cerebral palsy in cases of TTTS post laser
therapy has been reported, as opposed to the 4.2%
neurologic handicap rate reported by Chang et al [27].
The number and incidence of residual anastomoses that
failed to be coagulated during operation may, for a large
part, account for the differences in the incidence of
neurologic sequelae. More uncoagulated anastomoses
mean more neurologic complications. Early-onset TTTS
has a poor prognosis if untreated; 90% of fetuses would
not survive [30], let alone appear normal at follow-up.
Laser treatment dramatically improves the outcome of
early-onset TTTS.
Conclusion
Fetoscopic laser therapy for TTTS performed percuta-
neously before 26 weeks of gestation is a minimally
invasive treatment with few maternal complications,
with PROM becoming the main source of neonatal
complications [26]. Amnioreduction should be offered
to advanced stage (stage III and IV) cases only when
laser therapy is not available or when gestational age is
> 26 weeks. Laser therapy for TTTS can be performed
with minimal risk to the mother at centers staffed with
well trained maternal–fetal medicine specialists and
equipped with efficient instruments.
References
1. Benirschke K. The placenta in twin gestation. Clin Obstet
Gynecol 1990;33:18–31.
2. Machin GA, Bamforth F. Zygosity and placental anatomy
in 15 consecutive sets of spontaneously conceived triplets.
Am J Med Genet 1996;61:247–52.
3. Chasen ST, Al-Kouatly HB, Ballabh P, Skupski DW,
Chervenak FA. Outcomes of dichorionic triplet pregnan-
cies. Am J Obstet Gynecol 2002;186:765–7.
4. Quintero RA. Twin–twin transfusion syndrome. Clin Perinatol
2003;30:591–600.
5. Quintero R, Quintero L, Bornick P, Allen M, Johnson P. The
donor-recipient (D-R) score: in vivo endoscopic evidence to
support the hypothesis of a net transfer of blood from
donor to recipient in twin–twin transfusion syndrome.
Prenat Neonat Med 2000;5:84–91.
6. Fox C, Kilby MD, Khan KS. Contemporary treatments for
twin–twin transfusion syndrome. Obstet Gynecol 2005;105:
1469–77.
7. Gaziano EP, De Lia JE, Kuhlmann RS. Diamnionic mono-
chorionic twin gestations: an overview. J Matern Fetal Med
2000;9:89–96.
8. Machin GA. Some causes of genotypic and phenotypic dis-
cordance in monozygotic twin pairs. Am J Med Genet 1996;
61:216–28.
9. Robyr R, Quarello E, Ville Y. Management of fetofetal
transfusion syndrome. Prenat Diagn 2005;25:786–95.
10. Senat MV, Deprest J, Boulvain M, Paupe A, Winer N, Ville Y.
Endoscopic laser surgery versus serial amnioreduction for
severe twin-to-twin transfusion syndrome. N Engl J Med
2004;351:136–44.
11. Cunningham FG, MacDonald PC, Gant NF, Leveno KJ,
Gilstrap LC, Hankins GDV, Clark SL, eds. Multifetal preg-
nancy. In: Williams Obstetrics, 20th edition. Stamford, CT:
Appleton & Lange, 1996.
12. De Lia JE. Twin transfusion syndrome: successful in utero treat-
ment with digoxin. Int J Gynaecol Obstet 1985;23:197–201.
Taiwanese J Obstet Gynecol • December 2006 • Vol 45 • No 4300
Y.L. Chang
Figure 7. Placenta of twin–twin transfusion syndrome post
laser therapy.
Taiwanese J Obstet Gynecol • December 2006 • Vol 45 • No 4 301
Fetoscopic Laser Therapy for TTTS
13. De Lia JE. Theoretical treatment of placental vascular anom-
alies with neodymium:YAG laser via fetoscopy. Am J Obstet
Gynecol 1985;151:1126–7.
14. De Lia JE, Cruikshank DP, Keye WR, Jr. Fetoscopic
neodymium: YAG laser occlusion of placental vessels in
severe twin–twin transfusion syndrome. Obstet Gynecol
1990;75:1046–53.
15. Ville Y, Hyett J, Hecher K, Nicolaides K. Preliminary experi-
ence with endoscopic laser surgery for severe twin–twin
transfusion syndrome. N Engl J Med 1995;332:224–7.
16. Quintero RA, Morales WJ, Allen MH, Bornick PW, Johnson
PK, Kruger M. Staging of twin–twin transfusion syndrome. 
J Perinatol 1999;19:550–5.
17. Quintero RA, Morales WJ, Mendoza G, Allen M, Kalter CS,
Giannina G, Angel JL. Selective photocoagulation of pla-
cental vessels in twin–twin transfusion syndrome: evolu-
tion of a surgical technique. Obstet Gynecol Surv 1998;53:
S97–103.
18. Quintero RA, Comas C, Bornick PW, Allen MH, Kruger M.
Selective versus non-selective laser photocoagulation of pla-
cental vessels in twin-to-twin transfusion syndrome. Ultrasound
Obstet Gynecol 2000;16:230–6.
19. Quintero RA, Bornick PW, Allen MH, Johson PK. Selective
laser photocoagulation of communicating vessels in severe
twin–twin transfusion syndrome in women with an anterior
placenta. Obstet Gynecol 2001;97:477–81.
20. Danskin FH, Neilson JP. Twin-to-twin transfusion syndrome:
what are appropriate diagnostic criteria? Am J Obstet Gynecol
1989;161:365–9.
21. Fisk NM, Borrell A, Hubinont C, Tannirandorn Y, Nicolini U,
Rodeck CH. Fetofetal transfusion syndrome: do the neonatal
criteria apply in utero? Arch Dis Child 1990;65:657–61.
22. Fisk NM, Galea P. Twin–twin transfusion—as good as it
gets? N Engl J Med 2004;351:182–4.
23. Quintero RA, Dickinson JE, Morales WJ, Bornick PW,
Bermudez C, Cincotta R, Chan FY, Allen MH. Stage-based
treatment of twin–twin transfusion syndrome. Am J Obstet
Gynecol 2003;188:1333–40.
24. Quintero RA, Kontopoulos EV, Chmait R, Bornick PW,
Allen M. Management of twin–twin transfusion syndrome
in pregnancies with iatrogenic detachment of membranes
following therapeutic amniocentesis and the role of interim
amniopatch. Ultrasound Obstet Gynecol 2005;26:628–33.
25. Lewi L, Jani J, Deprest J. Invasive antenatal interventions in
complicated multiple pregnancies. Obstet Gynecol Clin North
Am 2005;32:105–26.
26. Yamamoto M, El ML, Robyr R, Leleu F, Takahashi Y, Ville Y.
Incidence and impact of perioperative complications in
175 fetoscopy-guided laser coagulations of chorionic plate
anastomoses in fetofetal transfusion syndrome before 26
weeks of gestation. Am J Obstet Gynecol 2005;193:1110–6.
27. Chang YL, Chmait RH, Bornick PW, Allen MH, Quintero
RA. The role of laser surgery in dissecting the etiology of
absent or reverse end-diastolic velocity in the umbilical
artery of the donor twin in twin–twin transfusion syn-
drome. Am J Obstet Gynecol 2006;195:478–83.
28. Robyr R, Lewi L, Salomon LJ, Yamamoto M, Bernard JP,
Deprest J, Ville Y. Prevalence and management of late fetal
complications following successful selective laser coagula-
tion of chorionic plate anastomoses in twin-to-twin trans-
fusion syndrome. Am J Obstet Gynecol 2006;194:796–803.
29. Lopriore E, van Wezel-Meijler G, Middeldorp JM, Sueters M,
Vandenbussche FP, Walther FJ. Incidence, origin, and char-
acter of cerebral injury in twin-to-twin transfusion syndrome
treated with fetoscopic laser surgery. Am J Obstet Gynecol
2006;194:1215–20.
30. Gaziano EP, De Lia JE, Kuhlmann RS. Diamnionic mono-
chorionic twin gestations: an overview. J Matern Fetal Med
2000;9:89–96.
